Enterprise Value

71.4B

Cash

8.96B

Avg Qtr Burn

N/A

Short % of Float

1.31%

Insider Ownership

2.54%

Institutional Own.

89.64%

Qtr Updated

03/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Evkeeza (evinacumab) Details
Homozygous familial hypercholesterolemia

Approved

Update

Kevzara (sarilumab) Details
Polymyalgia rheumatica

Approved

Quarterly sales

EYLEA (aflibercept) Details
Diabetic retinopathy

Approved

Quarterly sales

EYLEA (aflibercept) Details
Retinopathy of prematurity

Approved

Quarterly sales

PDUFA

Approval decision

Pozelimab (C5 ANTIBODY) Details
Rare diseases, CD55-deficient protein-losing enteropathy

PDUFA

Approval decision

Aflibercept 8mg Details
Diabetic macular edema

PDUFA

Approval decision

Aflibercept 8mg Details
Wet age-related macular degeneration

PDUFA

Approval decision

Dupixent (DUPILUMAB) Details
Skin disease/disorder, Atopic dermatitis

Phase 3

Data readout

Dupixent Details
Chronic obstructive pulmonary disease

Phase 3

Update

Linvoseltamab(BCMAXCD3) Details
Blood cancer, Cancer, Multiple myeloma

Phase 2

Update

Fianlimab + Libtayo® (cemiplimab) Details
Melanoma, Advanced malignancies

Phase 1

Update

Dupixent Details
Chronic inducible urticaria

Failed

Discontinued